EBS SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Emergent BioSolutions Inc. For Possible Securities Law Violations

NEW YORK CITY, NY / ACCESS Newswire / August 10, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Emergent BioSolutions Inc. ("Emergent BioSolutions Inc.") (NYSE:EBS) concerning potential violations of the federal securities laws.

Emergent BioSolutions shareholders absorbed a sharp decline after the Company reduced its FY2026 revenue guidance to $645-$675 million, down from the $720-$760 million range management had reaffirmed on its April 30, 2026 earnings call.

The timeline is specific. On February 26, 2026, Emergent issued initial FY2026 guidance of $720-$760 million in revenue and $135-$155 million in adjusted EBITDA. On that same call, Chief Financial Officer Richard S. Lindahl attributed softer NARCAN demand to the prolonged government shutdown and near-term market uncertainty, characterizing those factors as "we view as transient and not reflective of the long-term growth potential in this category." Management further stated that it expected NARCAN to maintain its leading market share, while the accompanying presentation stated that the Company had "maintained market leadership; pricing stabilized."

On April 30, 2026, Emergent reaffirmed its FY2026 revenue guidance of $720-$760 million, leaving the forecast unchanged from February. The Company simultaneously raised its adjusted EBITDA guidance to $155-$175 million from $135-$155 million.

Roughly three months later, on August 5, 2026, Emergent reduced its FY2026 revenue guidance to $645-$675 million from $720-$760 million, a $75 million reduction at the midpoint. The Company also reduced adjusted EBITDA guidance to $130-$150 million from $155-$175 million.

If you suffered a loss on your Emergent BioSolutions Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP